What's new in pediatric dermatology: Update for the pediatrician

Current Opinion in Pediatrics

Volumn 16, Issue 4, 2004, Pages 410-414

  Sidbury, Robert ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Imiquimod; Intravenous immunoglobulin; Pimecrolimus; Tacrolimus

Indexed keywords

CLOBETASOL; CORTICOSTEROID; IMIQUIMOD; IMMUNOGLOBULIN; IMMUNOMODULATING AGENT; PIMECROLIMUS; TACROLIMUS;

ATOPIC DERMATITIS; BLISTER; CLINICAL TRIAL; CONDYLOMA; CORRELATION ANALYSIS; CREAM; DERMATOLOGY; DRUG EFFECT; DRUG MECHANISM; DRUG SAFETY; EPIDERMOLYSIS; HEMANGIOMA; HUMAN; INFANCY; MEDICAL RESEARCH; MOLLUSCUM CONTAGIOSUM; NONHUMAN; PEDIATRICIAN; PEDIATRICS; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; STATISTICAL SIGNIFICANCE; STEVENS JOHNSON SYNDROME; VITILIGO;

ADJUVANTS, IMMUNOLOGIC; AMINOQUINOLINES; CHILD; CLINICAL TRIALS; DERMATITIS, ATOPIC; EPIDERMAL NECROLYSIS, TOXIC; HEMANGIOMA; HUMANS; IMMUNOGLOBULINS; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSIVE AGENTS; INFANT; MOLLUSCUM CONTAGIOSUM; SKIN; SKIN DISEASES; STEVENS-JOHNSON SYNDROME; TACROLIMUS; VITILIGO; WARTS;

EID: 3442890570     PISSN: 10408703     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mop.0000133081.24760.08     Document Type: Review

References (37)

1. Bernard L, Eichenfield L: Topical immunomodulators for atopic dermatitis. Curr Opin Pediatr 2002, 14:414-418.
2. Patel RR, Vander Strafen MR, Korman NJ: The safety and efficacy of tacrolimus therapy in patients younger than 2 years with atopic dermatitis. Arch Dermatol 2003, 139:1184-1186. This small, retrospective review demonstrates the efficacy of topical tacrolimus in infants with extensive dermatitis without significant systemic absorption or adverse effects.
3. Allen A, Siegfried E, Silverman R, et al.: Significant absorption of topical tacrolimus in 3 patients with Netherton syndrome. Arch Dermatol 2001, 137:747-750.
4. Ho VC, Gupta A, Kaufmann R, et al.: Safety and efficacy of non-steroid pimecrolimus 1% cream in the treatment of atopic dermatitis in infants. J Pediatr 2003, 142:155-162. This study demonstrates clinical improvement in infantile atopic dermatitis from pimecrolimus therapy in all measured end points, including severity scales and itch without significant systemic absorption or adverse events. Some infants had application site burning but no increase in infections was noted.
5. Allen BR, Lakhanpaul M, Morris A, et al.: Systemic exposure, tolerability, and efficacy of pimecrolimus cream 1% in atopic dermatitis patients. Arch Dis Child 2003, 88:969-973.
6. Eichenfield LF, Beck L: Elidel (pimecrolimus) cream 1%-a non-steroidal topical agent for the treatment of atopic dermatitis. J Allergy Clin Immunol 2003, 111:1153-1165. This is an excellent, comprehensive starting point for clinicians wanting to familiarize themselves with the indications, mechanism of action, safety, and efficacy studies for pimecrolimus and atopic dermatitis.
7. Kovacs SO: Vitiligo. J Am Acad Dermatol 1998, 38:647-666.
8. Jimbow K: Vitiligo. Therapeutic advances. Dermatol Clin 1998, 16:399-407.
9. Travis LB, Weinberg JM, Silverberg NB: Successful treatment of vitiligo with 0.1% tacrolimus ointment. Arch Dermatol 2003, 139:571-574.
10. Fujisawa Healthcare Inc.: Protopic package insert. Deerfield, IL: Fujisawa Healthcare Inc.; 2000.
11. Lepe V, Moncada B, Castenedo-Cazares JP, et al.: A double blind randomized trial of 0.1% tacrolimus vs 0.05% clobetasol for the treatment of childhood vitiligo. 2003, 139:581-585. This head-to-head comparison between a topical steroid and tacrolimus shows comparable efficacy and a better side effect profile for tacrolimus.
12. Majewski S, Pniewski T, Malejczyk M, et al.: Imiquimod is highly effective for extensive hyperproliferative condyloma in children. Pediatr Dermatol 2003, 20:440-442.
13. Micali G, Laccarrubba F, Nasca MR, et al.: The use of imiquimod 5% for the treatment of basal cell carcinoma as observed in Gorlin's syndrome. Clin Exp Dermatol 2003, 28(suppl):19-23. An effective atraumatic topical treatment for basal cell carcinomas would be a tremendous boon for patients with Gorlin syndrome who otherwise must endure a lifetime of recurrent surgical excisions that result in marked scarring.
14. Stockfleth E, Ulrich C, Hauschild A, et al.: Successful treatment of basal cell carcinoma in a nevoid basal cell carcinoma syndrome with topic 5% imiquimod. Eur J Dermatol 2002, 12:569-572.
15. Sidbury R, Neuschler N, Neuschler E, et al.: Topically applied imiquimod inhibits vascular tumor growth in vivo. J Invest Dermatol 2003, 121:1205-1209. This study provides animal model evidence that imiquimod can slow vascular tumor growth.
16. Chang E, Boyd A, Nelson CC, et al.: Successful treatment of infantile hemangiomas with interferon alfa-2b. J Pediatr Hematol Oncol 1997, 19:237-244.
17. Barlow CF, Priebe CJ, Mulliken JB, et al.: Spastic diplegia as a complication of interferon alfa-2a treatment of hemangiomas of infancy. J Pediatr 1998, 132:527-530.
18. Martinez MI, Sanchez-Carpintero I, North PE, et al.: Infantile hemangioma: clinical resolution with 5% imiquimod cream. Arch Dermatol 2002, 138:881-884. This paper reports clinical resolution of uncomplicated infantile hemangiomas in the scalp using imiquimod therapy in two infants. Marked irritation in both patients was noted, suggesting that close follow-up and treatment interruption may be required if hemangiomas are treated with imiquimod.
19. Hengge UR, Cusini M: Topical immunomodulators for the treatment of external genital warts, cutaneous warts, and molluscum contagiosum. Br J Dermatol 2003, 149(suppl 66):15-19.
20. Hengge UR, Esser R, Schultewolter T, et al.: Self-administered topical 5% imiquimod for the treatment of common warts and molluscum contagiosum. Br J Dermatol 2000, 143:921-922.
21. Barba AR, Kapoor S, Bermen B: An open label safety study of topical 5% imiquimod cream in the treatment of molluscum contagiosum in children. Dermatol Online J 2001, 7:20.
22. Skinner RB Jr: Treatment of molluscum contagiosum with imiquimod 5% cream. J Am Acad Dermatol 2002, 47(suppl 4):S221-S224.
23. Bayerl C, Feller G, Goordt S: Experience in treating molluscum contagiosum in children with imiquimod 5% cream. Br J Dermatol 2003, 149(suppl 66):25-29.
24. Micali G, Dall'Oglio F, Nasca MR: An open label evaluation of the efficacy of imiquimod 5% cream in the treatment of recalcitrant subungual and periungual cutaneous warts. J Dermatol Treat 2003, 14:233-236.
25. Sidbury R, Hanifin JM: Topical immunomodulators. In: Fitzpatrick's Dermatology in General Medicine, edn 6. Edited by Freedberg IM, Eisen AZ, Wolff K, et al. McGraw-Hill; 2003:2359-2361.
26. Gibbs S, Harvey I, Sterling J, et al.: Local treatments for cutaneous warts. Cochrane Database Syst Rev 2003, 3:CD001781. This is an evidence-based review of therapies for the common wart. This review points to the paucity of good studies available on which to base our treatment of this common skin infection, and identifies salicylic acid preparations as the best-supported wart remedy.
27. Bigby M: At what rates do commonly used local treatments lead to complete disappearance of the treated wart? Arch Dermatol 2003, 139:801-802.
28. Focht DR III, Spicer C, Fairchok M: The efficacy of duct tape vs cryotherapy in the treatment of verruca vulgaris (the common wart). Arch Pediatr Adolesc Med 2002, 156:971-974.
29. Bachot N, Roujeau JC: Differential diagnosis of severe cutaneous drug eruptions. Am J Clin Dermatol 2003, 4:561-572. This is a thorough review of important cutaneous reactions to systemic medications, with a helpful section on the confusing nosology of SJS/TEN.
30. Halebian PH, Corden VJ, Madden MR, et al.: Improved burn center survival of patients with toxic epidermal necrolysis managed without corticosteroids. Ann Surg 1986, 204:503-512.
31. Viard I, Wehrli A, Bullani R, et al.: Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 1998, 282:490-493.
32. Amato GM, Travia A, Ziino O: The use of intravenous high dose immunoglobulins (IVIg) in a case of Stevens-Johnson syndrome. Pediatr Med Chir 1992, 14:555-556.
33. Metry DW, Jung P, Levy ML: Use of intravenous immunoglobulin in children with Stevens-Johnson syndrome and toxic epidermal necrolysis: seven cases and review of the literature. Pediatrics 2003, 112:1430-1436. This is a very good presentation of both new pediatric cases and reviewed literature describing the use of IV Ig for this potentially life-threatening dermatosis. In this series most cases of SJS/TEN were caused by medications. IV Ig seemed to halt progression of disease and corticosteroids appeared to prolong IV Ig response time.
34. Prins C, Kerdel FA, Padilla RS, et al.: Treatment of toxic epidermal necrolysis with high-dose intravenous immunoglobulins. Arch Dermatol 2003, 139:26-32.
35. Trent JT, Kirsner RS, Romanelli P, et al.: Analysis of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis using Scorten: the Miami experience. Arch Dermatol 2003, 139:39-43.
36. Bachot N, Revuz J, Roujeau J-C: Intravenous immunoglobulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis: a prospective noncomparative study showing no benefit on mortality or progression. Arch Dermatol 2003, 139:33-36.
37. Stahl M, Schifferli JA: The renal risks of high-dose intravenous immunoglobulin treatment. Nephrol Dial Transplant 1998, 13:2182-2185.